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Introduction
For nearly 50 years, orchidectomy followed by adjuvant
irradiation1 of the pelvic and para-aortic nodes has been
the standard treatment for stage I seminoma, with
overall cure rates approaching 100%.2 However,
surveillance studies, in progress for more than 20 years,
indicate that about 80% of these patients are cured by
orchidectomy alone, although stratiﬁcation by risk
factors can be used to deﬁne patients at an increased risk
of relapse.3 Because surveillance has some disadvantages
(particularly difﬁculties in the detection of relapse and
patients defaulting follow-up),4,5 and irradiation in these
patients could be associated with an increased risk and
mortality from late non-germ-cell cancers and
cardiovascular events,1,6–8 research has attempted to
reduce the amount of radiotherapy given. The UK
Medical Research Council (MRC) has undertaken two
trials to reduce the adjuvant radiation dose9 and the
extent of the irradiated volume,2 and demonstrated no
loss of effectiveness with respect to relapse-free survival.
However, the latter study,2 in which researchers
compared para-aortic (PA) strip with dog-leg (DL) ﬁeld
irradiation (ie, PA strip plus ipsilateral iliac and inguinal
ﬁelds), had a signiﬁcantly increased rate of pelvic relapse
in the PA only group.2
The discovery that metastatic seminomas were more
chemosensitive10–12 and radiation sensitive13 than non-
seminomas10–12 led to researchers investigating the use of
two courses and then one course of carboplatin4,5,14 as a
possible alternative to radiation—the relapse rate was
less than 3% when the dose was increased to AUC7
(AUC=area under the dose-time concentration curve).14
This dose was selected for a randomised, collaborative
trial to compare this carboplatin approach with
radiotherapy. We report the initial results of this study
after a median of 4 years’ follow-up. 
Methods
Patients 
Inclusion criteria were patients with: histologically
conﬁrmed seminomatous germ-cell tumours (classic or
anaplastic) at pathological stage pT1–pT315 (excluding
patients with pT4; involvement of the cut end of the
spermatic cord); clinical and radiological stage I disease
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Summary
Background Adjuvant radiotherapy is effective treatment for stage I seminoma, but is associated with a risk of late
non-germ-cell cancer and cardiovascular events. After good results in initial studies with one injection of carboplatin,
we undertook a large randomised trial to compare the approaches of radiotherapy with chemotherapy in seminoma
treatment.
Methods Between 1996 and 2001, 1477 patients from 70 hospitals in 14 countries were randomly assigned to receive
radiotherapy (para-aortic strip or dog-leg ﬁeld; n=904) or one injection of carboplatin (n=573; dose based on the
formula 7[glomerular ﬁltration rate25] mg), at two trial centres in the UK and Belgium. The primary outcome
measure was the relapse-free rate, with the trial powered to exclude absolute differences in 2-year rates of more than
3%. Analysis was by intention to treat and per protocol. This trial has been assigned the International Standard
Randomised Controlled Trial Number ISRCTN27163214.
Findings 885 and 560 patients received radiotherapy and carboplatin, respectively. With a median follow-up of 4 years
(IQR 3·0–4·9), relapse-free survival rates for radiotherapy and carboplatin were similar (96·7% [95% CI 95·3–97·7]
vs 97·7% [96·0–98·6] at 2 years; 95·9% [94·4–97·1] vs 94·8% [92·5–96·4] at 3 years, respectively; hazard ratio 1·28
[90% CI 0·85–1·93], p=0·32). At 2 years’ follow-up, the absolute differences in relapse-free rates
(radiotherapy–chemotherapy) were –1·0% (90% CI –2·5 to 0·5) by direct comparison of proportions, and 0·9%
(–0·5 to 3·0) by a hazard-ratio-based approach. Patients given carboplatin were less lethargic and less likely to take
time off work than those given radiotherapy. New, second primary testicular germ-cell tumours were reported in ten
patients allocated irradiation (all after para-aortic strip ﬁeld) and two allocated carboplatin (5-year event rate 1·96%
[95% CI 1·0–3·8] vs 0·54% [0·1–2·1], p=0·04). One seminoma-related death occurred after radiotherapy and none
after carboplatin.
Interpretation This trial has shown the non-inferiority of carboplatin to radiotherapy in the treatment of stage I
seminoma. Although the absence of disease-related deaths and preliminary data indicating fewer second primary
testicular germ-cell tumours favour carboplatin use, these ﬁndings need to be conﬁrmed beyond 4 years’ follow-up.
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with normal -fetoprotein concentrations before and
after orchidectomy; and normal concentrations of
human chorionic gonadotropin after orchidectomy.
Patients who gave written, informed consent were
randomly assigned to the two treatments within 8 weeks
of orchidectomy by telephone call to either the MRC
Clinical Trials Unit, London, or the EORTC (European
Organisation for Research and Treatment of Cancer)
Data Centre, Brussels, with treatment to begin within
2 weeks of registration. Approval from local research
ethics committees was obtained by all participating
centres. The main randomisation of the study was
between irradiation (optional sub-randomisation with
respect to dose took place at the same time) and one
injection of carboplatin at a dose of AUC7.
Randomisation was effected by minimisation, with
stratiﬁcation by centre; previous inguinal, pelvic, or
scrotal surgery; and intended radiotherapy schedule
(randomised or elected).
Procedures
Carboplatin doses were given intravenously and
calculated by a formula based on the AUC estimate of
drug disappearance from the body. The dose was
calculated by the formula 7(glomerular ﬁltration rate
[GFR, mL/min]25) mg.16 EDTA was the preferred
method for assessment of GFR. A 24-h urinary
collection-based creatinine clearance was allowed, but
not one calculated by the Cockcroft formula, which is
known to be less accurate. 
Radiotherapy doses were determined by optional
randomisation between 30 Gy in 15 fractions and 20 Gy
in 10 fractions to the PA or DL ﬁeld (recommended for
patients with previous inguinal surgery), similar to our
previous trials.2,9 If a dose was not chosen by
randomisation, schedules delivering a total dose of
between 20 Gy and 30 Gy were allowed after discussion
with the principal investigators.
Clinical and tumour marker assessments took place
every 3 months in year 1, every 4 months in year 2, every
6 months in year 3, and will continue yearly until
year 10. Chest radiographs were done at 6, 12, 20, 30,
and 36 months, and CT scans of the chest, abdomen,
and pelvis done at 12, 24, and 36 months. At relapse,
standard chemotherapy regimens for metastatic
seminomas were recommended, but those relapses that
were localised outside any previously irradiated volume
could be managed with radiotherapy at the treating
clinician’s discretion.
The primary outcome measure was the relapse-free
rate; death from any cause and any second cancer
incidence were also recorded. Particular attention was
made to distinguish between second primary testicular
germ-cells tumours and late non-germ-cell tumours
arising from other organs. Morbidity was assessed by
patients’ diary cards as used previously;9 these were
completed daily for 4 weeks and then weekly for another
8 weeks with primary analysis points at weeks 4 and 12.
The EORTC core Quality of Life Questionnaire (QLQ-
C303)17 was completed at baseline and at 3, 6, 12, and
24 months after randomisation.
Statistical analysis
The aim of the trial was to show the non-inferiority of
carboplatin over irradiation, irrespective of dose. Since
the equivalence of 30 Gy and 20 Gy had not been shown
when the trial had begun,9 the trial included an optional
randomisation between these doses. To increase the
overall power of the trial for both primary (radiotherapy
vs carboplatin) and secondary comparisons (30 Gy vs
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(n=904) (n=573)
Mean age (SD, years) 38·5 (9·8) 38·2 (9·0)
Raised concentration of human chorionic gonadotropin before 
orchidectomy 121 (13%) 88 (15%)
Previous ipsilateral operation 86 (10%) 56 (10%)
Median number of days from orchidectomy to treatment (IQR) 57 (46–70) 45 (33–56)
Eligibility
Restaged as stage II before treatment 4 2
On the basis of pre-randomised scans 2 2
On the basis of post-randomisation scans 2 0
Diagnosis changed to non-seminoma germ-cell tumour 4 0
Treatment compliance
Treatment information available 901 571
Received allocated treatment (n, %) 885 (98%) 560 (98%)
PA strip without scrotal shielding 668 ..
PA strip with scrotal shielding 97 ..
Dog-leg ﬁeld 118 ..
Not known 2 ..
Did not receive allocated treatment (n, %) 16 (2%) 11 (2%)
Received treatment from other group 5 7
Received no treatment 5 2
Received other chemotherapy 6 1
Received other treatment 0 1
Data are number of patients unless stated otherwise.
Table 1: Patients’ characteristics
1477 patients
            randomised 
854 followed up to relapse or 
         at least 2 years and one 
         discontinued intervention
544 followed up to relapse or 
         at least 2 years and none
         discontinued intervention
904 underwent intention-to-
         treat analysis
885 underwent per-protocol
         analysis
573 underwent intention-to-
         treat analysis
560 underwent per-protocol
          analysis
904 allocated radiotherapy
885 received allocated
         treatment
  16 did not receive allocated
         treatment
573 allocated carboplatin
560 received allocated
         treatment
   11 did not receive allocated
         treatment
Figure 1: Trial proﬁle
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20 Gy vs carboplatin), patients were randomly assigned
to radiotherapy and carboplatin in the ratio of 5:3;
therefore 30 Gy, 20 Gy, and carboplatin, where
applicable, were given in the ratio 2·5:2·5:3, respectively. 
If a 2-year relapse-free rate after radiotherapy of
96–97% was assumed, it was agreed that absolute
differences of 3–4% or more should be excluded.
Although the initial target size was 800 patients, this
number was revised to 1200 patients after rapid accrual.
Under the assumption of true equivalence, this would
enable a 3% difference to be excluded with 90% certainty
(=5%, one-sided). A minimum of 800 patients
randomly assigned between 30 Gy (n=250), 20 Gy
(n=250), and carboplatin (n=300) was assumed, which
would give 85% power to exclude a 4% absolute
difference in any pair-wise comparison.
Since the clinical equivalence of 30 Gy and 20 Gy has
now been shown,9 our analysis focused on the primary
comparison of radiotherapy with carboplatin. Relapse-
free rates were calculated with the Kaplan-Meier method
and compared by use of the log-rank test; hazard ratios
(HR) and CIs were calculated with Cox’s proportional
hazard regression model (HR1 favours radiotherapy).
The absolute differences in relapse rates at speciﬁc time
points and their 90% CIs were calculated by the direct
comparison of proportions and by application of the HR
(based on entire event-free curves) and its 90% CI to the
event-free rate of the control group at the time points of
interest (as lnP1/LnP2=HR, under the proportional
hazards assumption). Comparisons of categorical data
used 2 tests for binary data and 2 tests for trend for
ordered categories, such as grades for toxic effects. Both
intention-to-treat and per-protocol analyses were
undertaken, because poor compliance can bias results
towards equivalence in an intention-to-treat analysis.18
This trial has been assigned the International Standard
Randomised Controlled Trial Number
ISRCTN27163214.
Role of the funding source
The sponsor of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had full
access to all the data in the study and had ﬁnal
responsibility for the decision to submit for publication.
Results 
Between September, 1996, and March, 2001,
1477 patients from 70 hospitals in 14 countries were
randomly assigned to radiotherapy and carboplatin
(ﬁgure 1). Sub-randomisation between 30 Gy, 20 Gy, and
carboplatin was done in 937 patients (n=294, 289, and
354, respectively).
Table 1 shows the patients’ baseline characteristics.
Overall, mean age was 38·4 years (SD 9·6), 209 (14%)
patients had raised concentrations of human chorionic
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Figure 2: Patients’ diary card data
(A) Comparison between radiotherapy and carboplatin treatment. (B) Comparison between 30 Gy and 20 Gy doses of radiotherapy and carboplatin treatment. 
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gonadotropin before orchidectomy, and 142 (10%) a
previous ipsilateral inguinal operation. With respect to
treatment compliance, 1472 patients in both groups
provided treatment information. Four patients allocated
radiotherapy (0·4%) and two allocated carboplatin
(0·3%) had metastatic disease before starting treatment,
and therefore received treatment appropriate to their
clinical stage. For two patients in each group, their
stages were revised on the basis of re-interpretation of
the baseline scans; for the two remaining patients given
radiotherapy, this revision was based on further scans
taken before starting treatment but after randomisation.
A further four patients allocated radiotherapy had their
diagnosis changed to non-seminoma after random-
isation and were treated with chemotherapy. All these
patients were included in the intention-to-treat analysis,
but those who did not receive their allocated treatment
were excluded from the per-protocol analysis.
Of patients who received radiotherapy, PA and DL
irradiation ﬁelds were used in 735 (87%) and in
118 (13%) patients, respectively. 30 Gy doses were given
to 477 (54%) patients, 20 Gy to 322 (36%), and 23–29 Gy
to 82 (9%). Of patients allocated carboplatin, 506 (92%)
received the correct dose within limits of 10%, with
34 (6%) receiving higher and ten (2%) receiving lower
doses. Of adverse effects, analysis showed signiﬁcantly
less thrombocytopenia in individuals receiving
radiotherapy than those receiving carboplatin (grade 1 or
2, 12 [2%] patients vs 58 [12%]; grade 3 or 4, none vs
17 [4%]; p0·0001), although no associated bleeding
was reported. Signiﬁcantly more dyspepsia in patients
receiving radiotherapy than in those receiving
carboplatin was seen (127 [17%] vs 40 [8%], p0·0001).
Diary cards were completed by about 60% of patients in
each group (ﬁgure 2). Although carboplatin was slightly
more toxic at 72 h than radiotherapy (ﬁgure 2, A),
afterwards patients with carboplatin were signiﬁcantly
less lethargic, and had a higher proportion returning to
work. This trend was still in favour of carboplatin,
although less so, when the radiation dose was broken
down to either 30 Gy or 20 Gy (ﬁgure 2, B). 
Median follow-up is now at 4 years (IQR 3·0–4·9) with
1337 (91%) patients having at least 2 years of follow-up
recorded. Table 2 shows events by allocated treatment,
with details of relapse and late events. Relapse-free rates
(ﬁgure 3) for radiation compared with carboplatin were
96·7% (95% CI 95·3–97·7) versus 97·7% (96·0–98·6) at
2 years’ follow-up and 95·9% (94·4–97·1) versus 94·8%
(92·5–96·4) at 3 years’ follow-up (intention-to-treat
HR=1·28, 90% CI 0·85–1·93, p=0·32; per-protocol
HR=1·30, 0·85–1·99, p=0·31). The absolute differences
in relapse-free rates (radiotherapy– chemotherapy) were
–1·0% (90% CI –2·5 to 0·5) at 2 years’ follow-up and
1·1% (–1·0 to 3·2) at 3 years by direct comparison of
proportions, and 0·9% (–0·5 to 3·0) at 2 years and 1·1%
(–0·6 to 3·7) at 3 years with the HR-based approach. The
90% CIs exclude an increase in relapse rate in the
carboplatin group of more than 3·0% at 2 years and more
than 3·7% at 3 years by use of both intention-to-treat and
per-protocol analyses. 
Patients receiving carboplatin relapsed more
frequently in the PA nodes than did those receiving
radiotherapy (74% vs 9% postradiation, table 2).
However, mediastinal or supraclavicular relapse
(stage III), and pelvic-node relapse were more common
after radiotherapy than after chemotherapy. Only one of
the ten patients with isolated pelvic recurrence had
previous inguinal surgery. Relapses arose in 32 patients
in the irradiation group (initial salvage treatment
bleomycin, etoposide, cisplatin [BEP], n=22; EP, n=10);
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(n=904) (n=573)
Relapses
Relapses before treatment or restaging 4 2
Relapses after treatment 32 27
Total 36 29
Stage of relapses after treatment (n, %)
Marker only 1 (3%) 0
Stage II (subdiaphragmatic nodal sites only) 13 (41%) 20 (74%)
Maximum para-aortic node diameter 3 cm* 2 (6%) 10 (37%)
Maximum para-aortic node diameter 3 cm 1 (3%) 9 (33%)
Size not known 0 1 (4%)
Pelvic nodes only 10 (31%)† 0
Stage III (supradiaphragmatic nodal sites) 14 (44%) 3 (11%)
Stage IV (haematogenous spread) 4 (13%) 3 (11%)
Stage unconﬁrmed 0 1 (4%)
New primary cancers
Germ-cell tumours‡ 10 2
Other§ 4 3
Total 14 5
Cause of death
Seminoma 1 0
Other cancer 2 1
Unrelated cause 2 1
Total 5 2
Data are number of events unless stated otherwise. *One patient per group positive for human chorionic gonadotropin. †All
patients received PA strip only, and only one had previous inguinal surgery. †Timing of second tumours (months from initial
treatment): radiotherapy, 3, 6, 17, 23, 24, 28, 30, 37, 47, and 49 months; carboplatin, 30 and 44 months. §Timing of tumours:
radiotherapy, gastric cancer (18 months), bladder transitional-cell carcinoma (36), pancreatic cancer (14), melanoma (41);
carboplatin, lymphoma (78), gastric cancer (8), lung cancer (24). 
Table 2: Events after allocated treatment
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573 552 523 425 288 124 31 6
Radiotherapy
Carboplatin
Figure 3: Relapse-free rate by allocated treatment
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29 of these patients were disease-free after ﬁrst-line
salvage (median postrelapse follow-up 1·5 years,
IQR 1·0–2·2), and three failed ﬁrst-line salvage
chemotherapy (all BEP). The carboplatin group had
27 relapses; all had been salvaged (initial salvage
treatment BEP, n=16; EP, n=5; radiation, n=6) and had a
median of 1·8 years of follow-up (IQR 1·6–2·2) after
relapse. 
Although one death occurred from seminoma among
the patients given radiotherapy, no disease or treatment-
related deaths had arisen after carboplatin. Deaths from
other causes have since occurred in four radiotherapy
patients (two car accidents, one gastric cancer, one B-cell
lymphoma) and in two carboplatin patients (one
cardiomyopathy, one gastric cancer).
Table 2 shows that the radiotherapy and carboplatin
groups had ten versus two second germ-cell tumours in
the contralateral testis, and four versus three non-germ-
cell second cancers, respectively. Most of the
radiotherapy patients (n=668) received PA strip
irradiation with no scrotal shielding; of these
individuals, the rate of new germ-cell tumours was
signiﬁcantly higher than that for carboplatin patients
(5-year event rate 1·96% [95% CI 1·0–3·8] vs 0·54%
[0·1–2·1]; log-rank test, p=0·04). Among the
118 patients treated with DL irradiation, no second
germ-cell tumours have yet been reported.
No signiﬁcant differences were seen between the
radiotherapy and carboplatin groups with respect to
gonadal function as measured by luteinising hormone,
follicle-stimulating hormone (FSH), or testosterone
when tested before treatment and at 24 months (data not
shown). However, when the radiotherapy group was
broken down according to irradiation ﬁeld, 12-month
FSH was signiﬁcantly higher (p=0·002) in the small
group receiving DL ﬁeld (n=35, 12-month median
14·5 IU/L [IQR 9·6–20·8], baseline 9·5 IU/L [7·5–18·0])
than in the carboplatin group (n=180, 10·0 IU/L
[7·1–13·5], 9·6 IU/L [6·9–12·9]), although the results
were similar in the carboplatin and PA strip groups
(n=216, 10·5 IU/L [7·7–16.0], 10·0 IU/L [7·0–14·2]).
Pretreatment FSH was signiﬁcantly increased in patients
who subsequently developed a second germ-cell tumour
(median 19·9 IU/L [IQR 17·0–39·1, n=7] vs 9·3 IU/L
[6·7–13·7, n=999], p=0·003, Mann-Whitney test).
Discussion
From our study, one injection of carboplatin at a dose of
AUC7 has shown, with a median of 4 years’ follow-up,
to be an effective adjuvant treatment for stage I
seminoma and similar in outcome to recent
radiotherapy schedules. As well as carboplatin having
fewer acute toxic effects than radiotherapy, some
preliminary data indicate that carboplatin treatment
delays and possibly reduces the incidence of
contralateral second germ-cell tumours. Extended long-
term follow-up is needed to conﬁrm these ﬁndings and
ensure that no increased risks of late non-germ-cell
malignant disease and cardiovascular risk are seen, as in
the older radiotherapy schedules.
40–45% of patients with testicular germ-cell cancer
have stage I seminoma, which is now the most common
clinical problem in individuals with germ-cell tumours.
Surveillance studies have suggested that 15–20% of
these patients have undetected metastatic disease and a
meta-analysis of these studies3 has shown that the
factors associated with raised risk of relapse were
increasing tumour size (with a cut-off of 4 cm) and
pathological inﬁltration of the rete testis.
Seminomas are highly sensitive to radiotherapy and
chemotherapy, and cure rates for stage I disease exceed
99%. Therefore, survival is an unsuitable trial endpoint,
and randomised studies have instead focused on relapse-
free survival and toxic effects. Toxic effects are
important, since more than 80% of patients are cured by
orchidectomy. Two management approaches have
dominated clinical practice for the past 20 years—
irradiation and surveillance. Treatment with carboplatin
only can now be regarded as a third approach. Which
approach is preferable, and what future studies should
be considered?
Radiotherapy has been the accepted management
approach for at least ﬁve decades. Two MRC studies,
each reported with a median follow-up of 5 years,2,9 have
sought to reduce the toxic effects of radiotherapy but
maintain beneﬁt. The ﬁrst study investigated ﬁeld
reduction (ie, DL ﬁeld to PA strip),2 and the second
investigated the reduction in radiation dose from 30 Gy
to a new standard of 20 Gy.9 In both trials, efﬁcacy of the
experimental treatment was equal to the standard and
was better tolerated. Long-term follow-up of these cases
is needed because of the potential for late occurrence of
relapse in the pelvis2 and the need to determine whether
the raised risk of late non-germ cell cancers and
cardiovascular disease previously recorded in this young
(median age 38 years) population1 has been reduced in
parallel. 
Surveillance is a logical management strategy,
reserving all therapy postorchidectomy for patients with
disease progression; most chemonaive relapses are
salvaged successfully. However, this approach demands
patients’ compliance and the ability to do multiple
(number not yet deﬁned) CT scan studies over several
years, since relapse has been reported to occur as late as
10 years.3 Serum tumour markers are not always useful at
follow-up and a proportion of relapsing patients that are
managed with this approach will prove difﬁcult to
diagnose and will need intensive combined therapy
because of bulky abdominal or visceral disease. This
problem could also be the case if surveillance compliance
is poor and can leave lasting sequelae. Long-term follow-
up of patients from surveillance studies3 is needed to
investigate what proportion of the late non-germ-cell
cancer and cardiovascular risk in irradiated patients is
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due to treatment, and what proportion is due to the
hypothetical predisposition of patients who develop
seminoma. Evidence that at least a proportion of these
are not treatment-related is suggested by the ﬁnding that
at least half the late non-germ-cell cancers occur outside
the radiation ﬁeld6 and radiobiology studies show that the
lymphocytes of seminoma patients before radiation show
a raised incidence of reciprocal translocations.19
Carboplatin is now a third treatment choice that could
have important beneﬁts in countries where radiotherapy
equipment is scarce, despite data for its sole use in
randomised trials in metastatic disease that suggest a
higher relapse rate than that for cisplatin-containing
combinations.20 The relapse rate after AUC7 in this
study (5·2%) could clearly be improved. Given the
apparent dose response compared with Dieckmann and
colleagues’ relapse rate of 8·6%,21 in which patients
received an average of 28% lower dose than those in the
present study (based on 400 mg/m2), the most effective
dose could be even higher. This ﬁnding is supported by
data from phase II studies,22 and will undergo further
study.
Is current follow-up enough to conﬁrm that one
course of carboplatin is adequate treatment?
Carboplatin cannot be compared with DL ﬁeld studies
with 30 Gy that report 30 years’ follow-up. However, if
compared with the experimental radiotherapy schedules
(PA strip and 20 Gy), the maturity of all carboplatin data
from the present trial and elsewhere22 is equivalent. In
two phase II studies, follow-up is beyond 10 years14,23
with no recurrence reported after 3 years (table 3). From
this trial and these additional data, a dose of carboplatin
of AUC-7 seems likely to yield a relapse-free survival
comparable to that of radiotherapy. Furthermore, this
approach was associated with fewer toxic effects and a
more rapid return to work than even the group
receiving the shortened radiotherapy schedule.
However, extended follow-up is needed to record late
events and will continue indeﬁnitely by national records
when possible, once patients are discharged from
hospital follow-up.
An unexpected observation was the reduced incidence
of second contralateral germ-cell tumour in patients
receiving carboplatin compared with those receiving
irradiation. This difference is presumably due to the
effect of carboplatin on carcinoma in situ in the
contralateral testis. Invasive second germ-cell tumours
can occur years after cisplatin-based combination
chemotherapy is given to patients with proven
carcinoma in situ28 or an invasive tumour in the
contralateral testis.29 This fact suggests that
chemotherapy could be less effective against carcinoma
in situ than established metastases. Although this
ﬁnding is only preliminary, it clearly needs further
follow-up. There are anecdotal data suggesting stage I
seminoma patients receiving carboplatin have good
recovery of gonadal function, as measured by early
pregnancies and serial FSH concentrations in phase II
studies.11,30 Therefore, carboplatin could affect second
tumour development without causing the reduction in
sperm count2 and rise in FSH seen in DL ﬁeld patients.
Should there be future studies in this highly curable
condition? A meta-analysis of patients’ data from the
carboplatin experiments published so far, focusing on
the carboplatin dose, number of drug courses, and
incidence of second tumours, could add valuable
information. An alternative approach has been
reported in a study of selected low-risk patients who had
small tumours (4 cm) without rete testis involvement
(32% of cases) and who underwent surveillance. These
patients had a 4·2% relapse rate, whereas of the
remaining 68% of patients (high-risk) who were given
two courses of carboplatin AUC7 and were followed up
for a median 2 years, 2·4% relapsed.26 An audit of
patients’ and physicians’ preference if faced with
information on the options available would be useful, as
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Number of cases Follow-up Relapses (crude Second primary Germ-cell Non-germ-cell 
(months) relapse rate) germ-cell tumours tumour deaths tumour deaths†
Two courses of carboplatin
Oliver et al14 57 128 2 0 0 2/0
Reiter et al23 107 74 0 n/a 0 1/5
Steiner et al24 108 60 2 n/a 0 0
Aparicio et al25 60 52 2 0 0 1/3
Aparicio et al26* 204 20 5 n/a 0 n/a
Krege et al27 43 28 0 n/a 0 1/0
Dieckmann et al21 32 48 0 n/a 0 n/a
Total 611 20–128 11 (1·8%) 0 0 5 (1·3%)/8 (2·1%)
One course of carboplatin (dose)
Dieckmann et al21 (400 mg/m2) 93 48 8 (8·6%) 1 0 0
Present study (AUC7) 560 48 27 (4·8%) 2 0 2/0
Oliver et al14 (AUC7) 146 52 1 (0·7%) 1 0 0
Total 799 48–52 36 (4·5%) n/a 0 2 (0·25%)/0
n/a=not available. *High-risk patients only. †Cancer-related deaths/non-cancer-related deaths.
Table 3: Overview of stage I seminoma treated with adjuvant carboplatin 
Articles
has been done for non-seminomas with unexpected
variation.31
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